A Review on Resealed Erythrocytes as a Novel Drug Delivery System

Karra Geetha *

CMR College of Pharmacy, Kandlakoya, Medchal District, Hyderabad, Telangana, India.

Deshapaka Pravalika

CMR College of Pharmacy, Kandlakoya, Medchal District, Hyderabad, Telangana, India.

R Shireesh Kiran

CMR College of Pharmacy, Kandlakoya, Medchal District, Hyderabad, Telangana, India.


CMR College of Pharmacy, Kandlakoya, Medchal District, Hyderabad, Telangana, India.

Thatikonda Rajitha

CMR College of Pharmacy, Kandlakoya, Medchal District, Hyderabad, Telangana, India.

*Author to whom correspondence should be addressed.


The most prevalent form of blood cell is the red blood cell. RBCs resemble biconcave discs with a 7.8 mm diameter and a thickness of about 2.2 mm. There are two ways that erythrocytes can be used as carriers: Targeting a specific tissue or organ, for continuous or extended medication release. For the delivery of medications, various kinds of mammalian erythrocytes have been employed. There are numerous techniques, including the hypo-osmotic method, the dilution method, the dialysis method, the press well method, the isotonic osmotic lyses, the electrical breakdown method, the endocytosis method, the membrane perturbation method, the normal transport method, and the lipid fusion method. After erythrocytes have been loaded with the therapeutic drug, carrier cells are subjected to physical, cellular, and biological examinations. Several invitro tests have shown the value of carrier RBCs. The RBC mediated microinjection that occurs most frequently invitro. Today, a wide range of uses for resealed erythrocytes as medication carriers, enzyme replacement treatment, etc. have been proposed.

Keywords: RBCs, erythrocytes, resealed erythrocytes, bio carrier

How to Cite

Geetha, K., Pravalika, D., Kiran, R. S., Simmu, & Rajitha, T. (2024). A Review on Resealed Erythrocytes as a Novel Drug Delivery System. Asian Journal of Medicine and Health, 22(6), 188–197. https://doi.org/10.9734/ajmah/2024/v22i61036


Download data is not yet available.


Keshamma E, Sohi S, Harshita, Kumar V, Shanko A, Pasupulla AP, Kumar A. Digitalis purpurea Improve Obesity Inducing Alternation of Cardiac Infarction: A Meta Analysis. Journal of Advances in Medicine and Medical Research. 2022; 34(23):93–110. Available:https://doi.org/10.9734/jammr/2022/v34i234843

Shah N, Prajapati R, Gohil D, Sadhu P, Patel S. Niosomes: A promising novel nano carrier for drug delivery. Journal of Pharmaceutical Research International. 2021;33(48B):53–66. DOI: 10.9734/jpri/2021/v33i48B33260.

Raut Deepika B, Sakhare ram S, Dadgeketan K and Halle PD. Resealed erythrocytes drug delivery: A review. International Journal of Research in Pharmacy and Chemistry. 2013;3(2): 198204.

Ashok kumar, Mansiverma KK Jha. Resealed erythrocytes as a carrier for drugtargeting: A review. The pharma journal, 2012;1:8-15.

Pragya, Vaibhavrastogi. Resealed erythrocytes: A promising drug carrier’’ International Journal of Pharmacy and Pharmaceutical Sciences, 2012;4:75-90.

Gothoskar AV. Resealed erythrocytes: A review pharmatech.com. 2004;140-154.

Vyas SP, khar RK. Targeted and controlled drug delivery: Novel carrier systems. CBSpublisher’ sdistributors. 2002;387-416.

Ravikanth Gupta, “Resealederythrocytes: carrier for smart drug delivery’’ world journal of pharmaceutical research, 2014; 3:1722-1736.

R.P. Patel, M.J. Patel, N.A. Patel “An overview of resealed erythrocytes drug delivery. Journal of Pharmacy Research, 2009;2(6):1008-1012.

Ramesh Y, Shaik Yasmin, Sravyasilpa A, Raj kumar, Gobirath M. Resealed erythrocytes drug carrier systems’’ international journal of pharmaceutical and drug analysis, 2016;4:343349.

Sackmann Erich, Biological Membranes Architecture and Function., Handbook of Biological Physics, (ed. R.Lipowsky and E.Sackmann, vol.1, Elsevier, 1995. 2011; 2(5):1357-1373.

Patel RP, Patel MJ, Patel A. An overview of resealed erythrocytes drug deliver, R.P. Patel. Journal of Pharmacy Research. 2009;2(6):1008- 1012.

Tortara GJ, Derrickson B. The cardiovascular system the blood in principles of anatomy and physiology, New York, NY, 7th ed., 1993;669-672.

Guyton AC, Hall JE. Red blood cells, anemia and polycytemia, in test book of medical physiology, Saunders WB, Philadelphia, PA. 1996;425-433.

Ropars C, Chassaigne M, Nicoulau C. Advances in the Biosciences, Pergamon Press, Oxford. 1987;67.

Sackmann Erich. Biological membranes architecture and function handbook of biological Physics, ed. R. Lipowsky and E. Sackmann Elsevier. 1995;1.

Jaitely V, et al. Resealed erythrocytes: Drug carrier potentials and biomedical applications, Indian Drugs, 1996;33:589–594.

Alpar HO, Lewis DA. Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes, biochem. Pharmacol. 1985; 34:257–261.

Baker R. Entry of Ferritin into Human Red Cells during Hypotonic Haemolysis, Nature, 1967;215:424-425.

Sprandel U. Towards cellular drug targeting and controlled release of drugs by magnetic fields, Adv. Biosci. (Series), 1987;67:243–250.

Kinosita K, Tsong TY. Survival of sucrose-loaded erythrocytes in the circulation, nature, 1978;272:258–260.

Eichler HG, et al. In vivo Clearance of Antibody-Sensitized Human Drug Carrier Erythrocytes, Clin. Pharmacol. Ther, 1986;40:300–303.

Bhaskaran S, Dhir SS. Resealed erythrocytes as carriers for salbutamol sulphate. Indian Journal of Pharmaceutical Sciences. 1995;57(6):240

Carmen Gutierrez Millan, Maria Luisa Sayalero Marinero, Aranzazu Zarzuelo Castaneda and Jose M. Lanao. Drug, enzyme and peptide delivery using erythrocytes as carriers, Journal of Controlled Release. 2004;95(1): 27-49.

Mehrdad Hamidi, Adbolhossein Zarina, Mahshid Foroozesha and Soliman Mohammadi-Samania.Applications of carrier erythrocytes in delivery of biopharmaceuticals. Journal of Controlled Release. 2007;118(2):145-1

Cannon EP, Leung P, Hawkins A, Petrikovics I, DeLoach J, Way JL. Antagonism of cyanide intoxication with murine carrier erythrocytes containing bovine rhodanese and sodium thiosulfate. Journal of Toxicology and Environmental Health, Part A Current Issues. 1994;41(3): 267- 74.

Jain S, Jain NK, and Dixit VK. Erythrocytes based delivery of isoniazid: Preparation and In VitroCharacterization. Indian Drugs. 1995;32:471–476.

Hamidi M, et al. In vitro characterization of human intact erythrocytes loaded by Enalaprilat. Drug Delivery. 2001;8:231–237.

Updike SJ, Wakamiya RT. Infusion of Red Blood Cell- Loaded Asparaginase in Monkey. J. Lab. Clin. Med. 1983;101:679–691 4.

Sparrow RL, Sran A, Healey G, et al. In vitro measures of membrane changes reveal differences between red blood cells stored in saline- adenine-glucose-mannitol and AS-1 additive solutions: a paired study. Transfusion. 2014;54(3):560–568.

Sowemimo-Coker SO. Evaluation of an experimental filter designed for improving the quality of red blood cells (RBCs) during storage by simultaneously removing white blood cells and immunomodulators and improving RBC viscoelasticity and Band 3 proteins. Transfusion. 2014;54(3):592–601.

Hunault-Berger M, Leguay T, Huguet F, et al. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: the GRASPALL/GRAALL-SA2-2008 study. Am J Hematol. 2015;90(9):811– 818.

Bourgeaux V, Aufradet E, Campion Y, et al. Efficacy of homologous inositol hexaphosphateloaded red blood cells in sickle transgenic mice. Br J Haematol. 2012;157:357–369.

Rossi L, Serafini S, Cenerini L, et al. Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease. Biotechnol Appl Biochem. 2001;33(pt 2):8589.

Rossi L, Castro M, D’Orio F, et al. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol Dis. 2004;33(1):57–63.

Castro M, Rossi L, Papadatou B, et al. Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease. J Pediatr Gastroenterol Nutr. 2007;44(4): 423–426.

Menotta M, Biagiotti S, Bianchi M, et al. Dexamethasone partially rescues ataxia telangiectasia-mutated (ATM) deficiency in ataxia telangiectasia by promoting a shortened protein variant retaining kinase activity. J Biol Chem. 2012;287(49):41352–41363.

Chessa L, Leuzzi V, Plebani A, et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: Results of a phase 2 trial. Orphanet J Rare Dis. 2014;9(1):5.

Leuzzi V, Micheli R, D’Agnano D, et al. Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e98.